停用检查点抑制剂治疗后持续存在的免疫相关不良事件:患病率及对患者健康相关生活质量的影响
这项多中心横断面研究纳入200例停用ICI至少12周后的癌症患者和2705例非ICI诱导的自身免疫病患者,评估持续性irAEs的患病率及对生活质量的影响。长期/慢性irAEs在门诊ICI患者中分别占51.9%/35.5%,伴有长期/慢性irAEs的患者健康相关生活质量临床显著降低,慢性irAEs患者的生活质量与自身免疫病患者相似。
要点
- 停用ICI后长期/慢性irAEs在门诊患者中分别占51.9%/35.5%。
- 伴有长期/慢性irAEs的ICI患者EQ-Index和EQ-VAS评分临床显著降低。
- 慢性irAEs患者感觉关于副作用的告知不充分(p < 0.001)。
核心结论
- 停用ICI后持续性irAEs给患者带来显著负担,尤其在早期肿瘤阶段需仔细评估风险获益比,并告知患者潜在的长期后遗症。
研究设计与样本
- 多中心横断面研究,纳入200例停用ICI至少12周后的癌症患者(ICI患者)和2705例自身免疫病患者(AI患者),在德国门诊诊所和支持团体中招募。
主要发现
- 长期/慢性irAEs在门诊ICI患者中分别占51.9%/35.5%,包括关节痛(16.7%/16.1%)、肌痛(13.0%/14.0%)、甲状腺功能减退(11.1%/10.8%)、口干(7.4%/8.6%)、白癜风(13.0%/7.5%)和垂体炎(9.3%/7.5%)。
- 伴有长期/慢性irAEs的ICI患者与不伴有者相比,EQ-Index评分分别为0.767/0.752 vs 0.920/0.923(p < 0.001/0.001),EQ-VAS评分分别为52.2/52.0 vs 63.6/74.7(p =/< 0.040/0.001)。
- 多元线性回归分析证实慢性irAEs使HRQoL评分临床显著降低(EQ-Index/VAS评分:-0.163/-23.4,p < 0.001/0.001)。
- 伴有慢性irAEs的ICI患者的生活质量、自身免疫症状负担及相关治疗负担与未加重的自身免疫病患者相似。
- 伴有慢性irAEs的患者与不伴有者相比,感觉关于副作用的告知不充分(p < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) may induce persistent immune-related adverse events (irAEs). We investigated persistent irAEs and implications on patients' lives compared to non-ICI-induced autoimmune diseases (AIs). METHODS: The multicentre, cross-sectional study comprised 200 patients with cancer ≥12 weeks after ICI cessation (ICI-patients) and 2705 patients with AIs (AI-patients), recruited in German outpatient clinics and support groups. The prevalence of persistent irAEs subdivided in long-term (12 weeks to <12 months) and chronic irAEs (≥12 months) since ICI discontinuation, health-related quality of life (HRQoL) using the EuroQol 5D-5L (EQ-Index/VAS score), and burden of autoimmune symptoms and respective therapies were assessed. RESULTS: Long-term/chronic irAEs occurred in 51.9%/35.5% of outpatient ICI-patients, including arthralgia (16.7%/16.1%), myalgia (13.0%/14.0%), hypothyroidism (11.1%/10.8%), xerostomia (7.4%/8.6%), vitiligo (13.0%/7.5%) and hypophysitis (9.3%/7.5%). ICI-patients with long-term/chronic irAEs reported clinically significantly reduced HRQoL compared to ICI-patients without long-term/chronic irAEs (EQ-Index score: 0.767/0.752 versus 0.920/0.923, p < 0.001/0.001; EQ-VAS score: 52.2/52.0 versus 63.6/74.7, p =/< 0.040/0.001). Multiple linear regression analyses confirmed clinically significant reductions in HRQoL scores by chronic irAEs (EQ-Index/VAS score: -0.163/-23.4, p < 0.001/0.001). HRQoL, burden of autoimmune symptoms and burden of respective therapies in ICI-patients with chronic irAEs were similar to AI-patients with non-exacerbated AIs. Patients with chronic irAEs felt inadequately informed about side-effects compared to patients without chronic irAEs (p < 0.001). CONCLUSION: Persistent irAEs impose a significant burden on patients after ICI cessation. Especially in early tumour stages, risk-benefit ratios must be carefully evaluated, and patients need to be informed about potential long-term sequelae.
引用
- Schulz TU, Zierold S, Sachse MM, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life. Eur J Cancer. 2022. PMID: 36198246. doi:10.1016/j.ejca.2022.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。